Anticonvulsants in the Treatment of Behavioral and Psychological Symptoms in Dementia: A Systematic Review.

• What is the primary question addressed by this study? What is the efficacy and safety of non-benzodiazepine anticonvulsants for treating behavioral and psychological symptoms of dementia (BPSD)? • What is the main finding of this study? Our systematic review of clinical trials found that non-benzodiazepine anticonvulsants (i.e., carbamazepine, oxcarbazepine, valproate preparations, topiramate) are unlikely to be effective in BPSD, and may be associated with a higher prevalence of adverse effects than comparator treatments. The quality of existing evidence is low. • What is the meaning of the finding? Existing evidence does not support the use of non-benzodiazepine anticonvulsants as treatment for BPSD. Behavioral and psychological symptoms of dementia (BPSD) are common and impart a significant burden to patients, caregivers, and the health system. However, there are few pharmacological options for treating BPSD. We conducted a systematic review of clinical trials examining the efficacy of anticonvulsants in BPSD. We searched five electronic databases through January 2023, for randomized controlled trials and systematic reviews evaluating the efficacy of non-benzodiazepine anticonvulsants for the treatment of BPSD. We used the Cochrane risk of bias tool to ascertain the risk of bias in included trials. Because statistical pooling of results using meta-analysis was not feasible, we synthesized findings using the Cochrane Synthesis Without Meta-analysis reporting guidelines. We identified 12 studies, including randomized controlled trials (RCTs) and 1 systematic review. Five RCTs evaluating valproic acid were synthesized by a recent Cochrane review which concluded that this drug is likely ineffective for BPSD. We extracted data from 6 trials involving 248 individuals comparing non-benzodiazepine anticonvulsants to either placebo or risperidone. Four trials (n = 97 participants) evaluated carbamazepine, only one of which demonstrated an improvement in the Brief Psychiatric Rating Scale measuring agitation, hostility, psychosis, and withdrawal/depression (effect size: 1.13; 95% confidence interval [CI]: 0.54–1.73) relative to placebo. Adverse effects were more common in patients receiving carbamazepine (20/27; 74%) relative to placebo (5/24; 21%). There is low quality evidence that oxcarbazepine is likely ineffective and that topiramate may be comparable to risperidone. Anticonvulsants are unlikely to be effective in BPSD, although the quality of existing evidence is low. [ABSTRACT FROM AUTHOR]